Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia

Kazuaki Taguchi, Masahiko Kouroki, Takafumi Ohmura, Hirofumi Jono, Fumio Endo, Hideyuki Saito

研究成果: Article査読

10 被引用数 (Scopus)


Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.

ジャーナルPediatrics International
出版ステータスPublished - 2014

ASJC Scopus subject areas

  • 小児科学、周産期医学および子どもの健康


「Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。